Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V

R. Beverly Raney, James R. Anderson, Frederic G. Barr, Sarah S. Donaldson, Alberto S. Pappo, Stephen J. Qualman, Eugene S. Wiener, Harold M. Maurer, William M. Crist

Research output: Contribution to journalArticle

279 Citations (Scopus)

Abstract

Purpose To review the importance of prognostic factors in developing new protocols for children with rhabdomyosarcoma (RMS). Patients and Methods Four studies conducted by the Intergroup Rhabdomyosarcoma Study (IRS) Group from 1972 through 1991. Results Favorable prognostic factors are: (1) undetectable distant metastases at diagnosis; (2) primary sites in the orbit and nonparameningeal head/neck and genitourinary nonbladder/prostate regions; (3) grossly complete surgical removal of localized tumor at the time of diagnosis; (4) embryonal/botryoid histology; (5) tumor size ≤5 cm; and (6) age younger than 10 years at diagnosis. The IRS-V protocols are risk-based and refine therapy by reducing exposure to cyclophosphamide and radiation therapy (XRT) in patients at low risk while adding new, active agents such as topotecan or irinotecan to the standard therapy of vincristine, actinomycin D, and cyclophosphamide (VAC) plus XRT for patients with unfavorable histology or advanced disease. Collection of biologic specimens from patients with newly diagnosed disease continues to identify other factors that may distinguish patients with favorable features from those who need more intensive therapy. A new protocol that takes into account their previous treatment is needed for patients with recurrent disease. This program (being planned) does not include bone marrow/stem cell reconstitution because this strategy has thus far failed to improve survival rates of patients with metastases at diagnosis. Conclusion Better understanding of biologic differences and new, active agents are needed to improve outcome of patients with unfavorable features at presentation.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume23
Issue number4
StatePublished - Jan 1 2001

Fingerprint

Rhabdomyosarcoma
Sarcoma
irinotecan
Cyclophosphamide
Histology
Implosive Therapy
Neoplasm Metastasis
Topotecan
Specimen Handling
Dactinomycin
Vincristine
Orbit
Bone Marrow Cells
Prostate
Neoplasms
Neck
Radiotherapy
Stem Cells
Therapeutics
Survival Rate

Keywords

  • Adolescence
  • Childhood
  • Rhabdomyosarcoma
  • Undifferentiated sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life : A selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. / Beverly Raney, R.; Anderson, James R.; Barr, Frederic G.; Donaldson, Sarah S.; Pappo, Alberto S.; Qualman, Stephen J.; Wiener, Eugene S.; Maurer, Harold M.; Crist, William M.

In: American Journal of Pediatric Hematology/Oncology, Vol. 23, No. 4, 01.01.2001, p. 215-220.

Research output: Contribution to journalArticle

Beverly Raney, R. ; Anderson, James R. ; Barr, Frederic G. ; Donaldson, Sarah S. ; Pappo, Alberto S. ; Qualman, Stephen J. ; Wiener, Eugene S. ; Maurer, Harold M. ; Crist, William M. / Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life : A selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. In: American Journal of Pediatric Hematology/Oncology. 2001 ; Vol. 23, No. 4. pp. 215-220.
@article{aec8cb4257ac4ab9a24e6ccd2bf5887e,
title = "Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V",
abstract = "Purpose To review the importance of prognostic factors in developing new protocols for children with rhabdomyosarcoma (RMS). Patients and Methods Four studies conducted by the Intergroup Rhabdomyosarcoma Study (IRS) Group from 1972 through 1991. Results Favorable prognostic factors are: (1) undetectable distant metastases at diagnosis; (2) primary sites in the orbit and nonparameningeal head/neck and genitourinary nonbladder/prostate regions; (3) grossly complete surgical removal of localized tumor at the time of diagnosis; (4) embryonal/botryoid histology; (5) tumor size ≤5 cm; and (6) age younger than 10 years at diagnosis. The IRS-V protocols are risk-based and refine therapy by reducing exposure to cyclophosphamide and radiation therapy (XRT) in patients at low risk while adding new, active agents such as topotecan or irinotecan to the standard therapy of vincristine, actinomycin D, and cyclophosphamide (VAC) plus XRT for patients with unfavorable histology or advanced disease. Collection of biologic specimens from patients with newly diagnosed disease continues to identify other factors that may distinguish patients with favorable features from those who need more intensive therapy. A new protocol that takes into account their previous treatment is needed for patients with recurrent disease. This program (being planned) does not include bone marrow/stem cell reconstitution because this strategy has thus far failed to improve survival rates of patients with metastases at diagnosis. Conclusion Better understanding of biologic differences and new, active agents are needed to improve outcome of patients with unfavorable features at presentation.",
keywords = "Adolescence, Childhood, Rhabdomyosarcoma, Undifferentiated sarcoma",
author = "{Beverly Raney}, R. and Anderson, {James R.} and Barr, {Frederic G.} and Donaldson, {Sarah S.} and Pappo, {Alberto S.} and Qualman, {Stephen J.} and Wiener, {Eugene S.} and Maurer, {Harold M.} and Crist, {William M.}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "23",
pages = "215--220",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life

T2 - A selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V

AU - Beverly Raney, R.

AU - Anderson, James R.

AU - Barr, Frederic G.

AU - Donaldson, Sarah S.

AU - Pappo, Alberto S.

AU - Qualman, Stephen J.

AU - Wiener, Eugene S.

AU - Maurer, Harold M.

AU - Crist, William M.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose To review the importance of prognostic factors in developing new protocols for children with rhabdomyosarcoma (RMS). Patients and Methods Four studies conducted by the Intergroup Rhabdomyosarcoma Study (IRS) Group from 1972 through 1991. Results Favorable prognostic factors are: (1) undetectable distant metastases at diagnosis; (2) primary sites in the orbit and nonparameningeal head/neck and genitourinary nonbladder/prostate regions; (3) grossly complete surgical removal of localized tumor at the time of diagnosis; (4) embryonal/botryoid histology; (5) tumor size ≤5 cm; and (6) age younger than 10 years at diagnosis. The IRS-V protocols are risk-based and refine therapy by reducing exposure to cyclophosphamide and radiation therapy (XRT) in patients at low risk while adding new, active agents such as topotecan or irinotecan to the standard therapy of vincristine, actinomycin D, and cyclophosphamide (VAC) plus XRT for patients with unfavorable histology or advanced disease. Collection of biologic specimens from patients with newly diagnosed disease continues to identify other factors that may distinguish patients with favorable features from those who need more intensive therapy. A new protocol that takes into account their previous treatment is needed for patients with recurrent disease. This program (being planned) does not include bone marrow/stem cell reconstitution because this strategy has thus far failed to improve survival rates of patients with metastases at diagnosis. Conclusion Better understanding of biologic differences and new, active agents are needed to improve outcome of patients with unfavorable features at presentation.

AB - Purpose To review the importance of prognostic factors in developing new protocols for children with rhabdomyosarcoma (RMS). Patients and Methods Four studies conducted by the Intergroup Rhabdomyosarcoma Study (IRS) Group from 1972 through 1991. Results Favorable prognostic factors are: (1) undetectable distant metastases at diagnosis; (2) primary sites in the orbit and nonparameningeal head/neck and genitourinary nonbladder/prostate regions; (3) grossly complete surgical removal of localized tumor at the time of diagnosis; (4) embryonal/botryoid histology; (5) tumor size ≤5 cm; and (6) age younger than 10 years at diagnosis. The IRS-V protocols are risk-based and refine therapy by reducing exposure to cyclophosphamide and radiation therapy (XRT) in patients at low risk while adding new, active agents such as topotecan or irinotecan to the standard therapy of vincristine, actinomycin D, and cyclophosphamide (VAC) plus XRT for patients with unfavorable histology or advanced disease. Collection of biologic specimens from patients with newly diagnosed disease continues to identify other factors that may distinguish patients with favorable features from those who need more intensive therapy. A new protocol that takes into account their previous treatment is needed for patients with recurrent disease. This program (being planned) does not include bone marrow/stem cell reconstitution because this strategy has thus far failed to improve survival rates of patients with metastases at diagnosis. Conclusion Better understanding of biologic differences and new, active agents are needed to improve outcome of patients with unfavorable features at presentation.

KW - Adolescence

KW - Childhood

KW - Rhabdomyosarcoma

KW - Undifferentiated sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0035008973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035008973&partnerID=8YFLogxK

M3 - Article

C2 - 11846299

AN - SCOPUS:0035008973

VL - 23

SP - 215

EP - 220

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -